Sabby Management’s Hepion Pharmaceuticals HEPA Stock Holding History

Sabby Management’s Portfolio HEPA Stock Details HEPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-836,615	Closed	-$360K	–	53
2025 Q1	$360K	Buy	+836,615	New	+$8.15M	1.06%	18
2022 Q1	–	Sell	-20	Closed	-$23K	–	172
2021 Q4	$23K	Buy	+20	New	+$27.4K	﹤0.01%	181
2021 Q2	–	Sell	-306	Closed	-$560K	–	176
2021 Q1	$564K	Buy	+306	New	+$671K	0.11%	102
2020 Q4	–	Sell	-57	Closed	-$148K	–	129
2020 Q3	$178K	Buy	+57	New	+$205K	0.03%	101
2020 Q2	–	Sell	-73	Closed	-$128K	–	113
2020 Q1	$128K	Buy	+73	New	+$292K	0.05%	58
2019 Q4	–	Sell	-115	Closed	-$278K	–	80
2019 Q3	$278K	Buy	+115	New	+$334K	0.15%	59

Other funds holding HEPA

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Sabby Management's HEPA Position: Q2 2025 in Review

Sabby Management sold out of Hepion Pharmaceuticals (HEPA) in Q2 2025, closing a stake of 836,615 shares — an estimated $360K sold.

Sabby Management first reported a position in HEPA in Q3 2019 and held it in 6 quarters. The position peaked at $564K in Q1 2021. 4 funds tracked by Wall St. Rank hold HEPA as of Q2 2025.

Sabby Management reported no remaining Hepion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Sabby Management sold 836,615 Hepion Pharmaceuticals shares in Q2 2025, an estimated $360K.
Sabby Management first reported a position in Hepion Pharmaceuticals in Q3 2019 and held it in 6 quarters.
Sabby Management's Hepion Pharmaceuticals position peaked at $564K in Q1 2021.
4 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2025.

Based on Sabby Management's 13F filing for Q2 2025, filed 14 Aug 2025.